mass spectrometry is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.
Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.
| Property | Value | Notes |
|---|---|---|
| Principal proposed target | GABA-A receptor complex | Hypothesis derived mainly from animal pharmacology |
| Common behavioral assay | Elevated plus maze | Rodent test for anxiety-like behavior |
| Reported molecular marker | Hippocampal BDNF expression | Measured by immunoassay or mRNA quantification |
| Typical dosing route | Intranasal | Chosen to reduce first-pass metabolism |
| Reported plasma half-life | Minutes | Based on limited peptide stability data |
Characterization of Selank in a laboratory setting relies on standard peptide methods. Reverse-phase high-performance liquid chromatography separates the target from related impurities and provides a purity figure, commonly reported as 95 percent or higher. Mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, confirms the molecular mass and helps detect truncation or modification. Amino acid analysis can verify composition when a sequence-level check is needed. These techniques together establish identity and purity for a given lot.
Lyophilized Selank, the dry powder form, is generally stored frozen at minus 20 degrees Celsius or colder for long-term keeping. The solid is hygroscopic and should stay sealed, dry, and protected from light. Once dissolved, the peptide is less stable and is usually held refrigerated at 2 to 8 degrees Celsius for short periods. Repeated freezing and thawing is avoided because it can promote aggregation and loss of activity. Buffers and pH choice also affect how long a solution remains usable.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
== Neutron poisoning == A reactor can be unintentionally "shut down" by having an excess of neutron poisons in the reactor vessel. Neutron poisons are chemical byproducts of the nuclear reaction which absorb neutrons, lowering reactivity in the reactor and potentially stalling the reaction if enough poisons are allowed to build up. An example of this would be the Chernobyl disaster in 1986, when Reactor No. 4 suffered from a serious xenon-135 poisoning, which pushed the reactor into an unstable condition which later caused the accident. While neutron poisoning is not considered a shutdown in and of itself, it often requires that the reactor be shut down while the poisons are flushed from the system, as they can destabilise the reactor and cause it to behave unpredictably. Certain reactors, such as the CANDU reactor design (where it is called EPIS, or Emergency Poison Injection System), employ this phenomenon as part of their SCRAM procedure. When a SCRAM occurs, neutron poisons are injected into the reactor to immediately lower the reactivity of the reactor, at the same time or slightly prior to other shutdown mechanisms, such as control rods.
==== 3.D. Oxidoreduction-driven transporters ==== They include a number of transmembrane cytochrome b-like proteins including coenzyme Q - cytochrome c reductase (cytochrome bc1 ); cytochrome b6f complex; formate dehydrogenase, respiratory nitrate reductase; succinate - coenzyme Q reductase (fumarate reductase); and succinate dehydrogenase. See electron transport chain.
Vitamin D deficiency was found to be related to neurological manifestations and the presence of lymphoma among patients. Vitamin A levels were inversely associated with extraglandular manifestations of the disease. Saliva is a potential diagnostic tool for Sjögren's disease because the salivary component is changed after the onset of the disease. With the new miniaturization technology, called lab on a chip, the diagnosis can be more convenient. Concerning therapeutics, multiple monoclonal antibodies were under investigation in 2007. The most promising seemed to be the anti-CD20 rituximab and the anti-CD22 epratuzumab, while the anti-TNF-α and IFN-α seemed less effective. In 2014, the Sjögren's Foundation (previously the Sjögren's Syndrome Foundation) announced a five-year goal to halve the disease's average time to diagnosis. As of 2026, several investigational therapies were in late-stage clinical development for Sjögren's disease. In January 2026, the FDA granted ianalumab Breakthrough Therapy designation for Sjögren's disease. Other agents in phase III development include telitacicept and dazodalibep.
Many women believe that sagging (ptosis) is caused by the failure of the Cooper's ligaments to support the breast tissue. In fact, ptosis is partly determined by genetic factors, but a review found that the biggest factors are higher body mass index, larger breast size, significant weight loss, smoking, number of pregnancies, and age. Many women incorrectly believe that wearing a brassiere prevents their breasts from sagging later in life and that breasts cannot anatomically support themselves. But bra manufacturers have stated that because breasts are formed of fatty tissue and not muscle, bras only affect the shape of breasts while they are being worn. Pathologically heavy breasts may cause pain in the woman's upper thoracic area, but this may be due to a poorly-fitting bra. Numerous reports state that 80–85% of women are wearing the wrong bra size. In middle-aged women, breast ptosis is caused by a combination of factors. If the woman has had children, postpartum hormonal changes will cause the depleted milk glands to atrophy. Women who experience multiple pregnancies repeatedly stretch the skin envelope during engorgement while lactating. As a woman's breasts grow in size during repeated pregnancies, the Cooper's ligaments that maintain the position of the mammary glands against the chest are stretched and gradually lose strength. Breast tissue and suspensory ligaments may also be stretched if the woman is overweight or loses and gains weight.
Sources: en.wikipedia.org
T: + RC(O)CO2H → T=C(OH)R + CO2 T=C(OH)R + R'COOH → T! : + RC(O)CH(OH)R' Pyridoxal phosphate promotes decarboxylation of amino acids. Flavin-dependent decarboxylases are involved in transformations of cysteine. Iron-based hydroxylases operate by reductive activation of O2 using the decarboxylation of alpha-ketoglutarate as an electron donor. The decarboxylation can be depicted as such:
=== Applications for oceanography === Tracers are also used extensively in oceanography to study a wide array of processes. The isotopes used are typically naturally occurring with well-established sources and rates of formation and decay. However, anthropogenic isotopes may also be used with great success. The researchers measure the isotopic ratios at different locations and times to infer information about the physical processes of the ocean.
Moreover, there are some challenges in fabricating and applying graphene oxide based nanofilters for water desalination. The challenges include mechanical instability if nanofilters are in the form of nanosheets, cost strategy, surface flaws, and assembly. Therefore, there are more scopes in this area of research to be worked on for the betterment of the society.
Sources: en.wikipedia.org
Sex pheromones are probably important in earthworms because they live in a concealed subterranean environment where chemical signalling may play a crucial role in attracting a partner and in facilitating outcrossing. Outcrossing would provide the benefit of masking the expression of deleterious recessive mutations in progeny. (see Complementation). Copulation and reproduction are separate processes in earthworms. The mating pair overlap front ends ventrally and each exchanges sperm with the other. The clitellum becomes very reddish to pinkish in colour. Sometime after copulation, long after the worms have separated, the clitellum (behind the spermathecae) secretes material which forms a ring around the worm. The worm then backs out of the ring, and as it does so, it injects its own eggs and the other worm's sperm into it. Thus each worm becomes the genetic father of some of their offspring (due to its own sperm transferred to other earthworm) and the genetic mother (offsprings from its own egg cells) of the rest. As the worm slips out of the ring, the ends of the cocoon seal to form a vaguely onion-shaped incubator (cocoon) in which the embryonic worms develop. Hence fertilization is external. The cocoon is then deposited in the soil. After three weeks, 2 to 20 offspring hatch with an average of four. Development is direct that is without formation of any larva.
Delta waves, like all brain waves, can be detected by electroencephalography (EEG). Delta waves were originally defined as having a frequency between 1 and 4 Hz, although more recent classifications put the boundaries at between 0.5 and 2 Hz. They are the slowest and highest amplitude classically described brainwaves, although recent studies have described slower (<0.1 Hz) oscillations Delta waves begin to appear in stage 3 sleep, but by stage 4 nearly all spectral activity is dominated by delta waves. Stage 3 sleep is defined as having less than 50% delta wave activity, while stage 4 sleep has more than 50% delta wave activity. These stages have recently been combined and are now collectively referred to as stage N3 slow-wave sleep. During N3 SWS, delta waves account for 20% or more of the EEG record during this stage. Delta waves occur in all mammals, and potentially all animals as well. Delta waves are often associated with another EEG phenomenon, the K-complex. K-complexes have been shown to immediately precede delta waves in slow wave sleep. Delta waves have also been classified according to the location of the activity into frontal (FIRDA), temporal (TIRDA), and occipital (OIRDA) intermittent delta activity.
=== Announcement and development === We Happy Few was revealed on 26 February 2015, and publicly debuted at PAX East 2015, allowing attendees to go hands-on with a very early version of the project. During June 2015, Compulsion Games ran a successful Kickstarter campaign, raising US$266,163 of the target US$200,000 to fund the development of the game. About 2,000 of these supporters backed at levels to participate in the game's alpha-version testing alongside Compulsion's dedicated play-testing team of five, but Compulsion found this did not provide them enough feedback to know which way to take the narrative elements within the randomly generated world. Instead, Compulsion opted to open the game to an early access release in a playable state on various storefronts for Windows and on the Xbox One Xbox Game Preview program starting on 26 July 2016 as to be able to gain much more feedback. Part of their choice to use early access was to provide transparency of what the game was actually to be, wanting to avoid the pitfalls that happened with No Man's Sky on its release in August 2016. Compulsion found many were anticipating a AAA gaming experience from their small team, and thus wanted to make sure players were clear on what their goals were for We Happy Few. One issue faced during development in early access was managing the expectations of what We Happy Few was meant to be.
Sources: en.wikipedia.org
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.
Behavioral endpoints include time spent in open arms of the elevated plus maze and avoidance latencies. Biochemical endpoints include BDNF concentration, cytokine levels, and monoamine metabolite ratios in brain tissue.
Most published studies are small, originate from a limited number of laboratories, and lack independent replication. Dose-response relationships, measured brain exposure, and long-term outcomes are not well characterized.
Identity is confirmed by matching the retention time in reversed-phase chromatography against a reference standard and by measuring the molecular mass with mass spectrometry. Tandem mass spectrometry or amino acid analysis can verify the sequence of the seven residues. Because the peptide contains no aromatic amino acids, detection at 280 nm is not useful.